key: cord-0263855-1rdnxnuc authors: Prischich, Davia; del Dedo, Javier Encinar; Cambra, Maria; Prat, Judit; Camarero, Nuria; Nevola, Laura; Martín-Quirós, Andrés; Rebollo, Elena; Giralt, Ernest; Isabel Geli, María; Gorostiza, Pau title: Light-dependent inhibition of clathrin-mediated endocytosis in yeast date: 2021-04-01 journal: bioRxiv DOI: 10.1101/2021.04.01.432428 sha: 2b13ca8cf731c499d5c2ce1a3c94e17a0d6de805 doc_id: 263855 cord_uid: 1rdnxnuc Clathrin-mediated endocytosis (CME) is an essential cellular process, which is evolutionarily conserved among eukaryotes. Yeast constitutes a powerful genetic model to dissect the complex endocytic machinery, yet there is a lack of pharmacological agents that could complement genetics in selectively and reversibly interfere with CME in these organisms. TL2 is a light-regulated peptide inhibitor that targets the AP2/β-arrestin interaction and that can photocontrol CME with high spatiotemporal precision in mammalian cells. Here, we study endocytic protein dynamics by live-cell imaging of the fluorescently tagged coat-associated protein Sla1-GFP and demonstrate that TL2 retains its inhibitory activity in S. cerevisiae spheroplasts, thus providing a unique tool for acute and reversible CME modulation in yeast. Clathrin-mediated endocytosis (CME) is one of the major entry routes for extracellular material and plasma membrane (PM) into eukaryotic cells. The process is essential to internalize nutrients, to maintain PM homeostasis, and to regulate receptor turnover and signalling, among other cellular functions. Endocytic vesicles are also employed by pathogenic toxins, 1-3 bacteria, 4 and viruses 5 (including SARS-CoV-2) 6,7 to reach intracellular compartments, whereas dysfunctions in the pathway can result in several diseases including cancer, myopathies, and neuropathies 8 . The formation of an endocytic vesicle relies on the sequential and finely coordinated assembly of more than 60 molecular actors which are conserved between yeast and mammalian cells. Thus, Saccharomyces cerevisiae provides a convenient model system to study the process, delivering findings that can often be extrapolated to higher eukaryotes [9] [10] [11] . Yeast amenability to genetic manipulation, together with advances of live-cell fluorescence microscopy and time resolved electron microscopy, has allowed to examine CME dynamics with great spatiotemporal resolution, and couple the recruitment of particular proteins to specific membrane deformation steps [12] [13] [14] [15] [16] [17] . Several strategies can be used to selectively interfere with CME in order to study the role of specific interactions between endocytic proteins and to decipher the impact of CME on particular cellular processes. Classic genetic manipulation is time consuming and not straightforward, and it can result in compensatory cellular responses that complicate the interpretation of the results. In addition, loss-of-function mutations may result in non-viable strains or display pleiotropic phenotypes when the proteins involved have multiple functions. Reciprocally, genetic redundancy might hinder uncovering of bona fide protein functions. These limitations have prompted the search for chemical and pharmacological agents that can specifically, acutely, and reversibly manipulate CME 18 . However, only few chemical tools are known to effectively and specifically inhibit CME, and none of them have been reported to be effective in yeast (Fig. 1A) 19, 20 . To date, the actin polymerization inhibitor latrunculin A and the sterol sequestering filipin have been effectively used to manipulate endocytic uptake in yeast, but they have pleiotropic effects in many other cellular functions 19,21 . Among the reasons for this shortage of molecular tools is that the endocytic machinery is mainly driven by protein-protein interactions, which involve large contact surfaces that are difficult to tackle with small molecules 22 . Besides, most of these agents display reduced specificity and can affect other endocytic pathways or perturbate other cellular processes 23 . Fig. 1 A) Overview of clathrin-mediated endocytosis (CME) inhibitors. On the left, pharmacological agents targeting specific endocytic proteins classified according to their biological activity in mammalian cells, plants, and yeast. On the right, chemicals that perturbate CME via a pleiotropic mechanism of action. Limits and advantages of each approach have been covered in the literature 18, 20, [23] [24] [25] . B) Traffic Light 2 (TL2) and its structural alterations produced by exposure to light. Upon illumination with UV light (380 nm), the crosslinker photoisomerizes from trans (dark-adapted conformation) to cis, thus promoting a helical structure (on the right, in purple) and the correct orientation of those residues (in red) responsible for the interaction with AP2 (in grey). Exposure to green light (500 nm) or spontaneous thermal relaxation revert the crosslinker to its stable conformation, thus causing partial unfolding of the peptide and loss of activity (on the left, in green). Thus, it would be very useful to identify a pharmacological agent capable of interfering with CME in a specific, acute, and reversible way in yeast, to take advantage of this well-defined model for the study of endocytosis. Previously, Nevola et al. developed two Traffic Lights (TLs), photoswitchable inhibitors of CME 26 . TLs are based on the structure of the human β-arrestin C-terminal peptide (BAP-long), which binds to the appendage of the β2-adaptin subunit of AP2 , the major endocytic clathrin adaptor in mammalian cells 27, 28 . Light regulation was introduced by stapling the structures with a photoresponsive bridge that upon trans-cis isomerization can modulate the helical content, and therefore, the inhibitory activity of the peptides 29, 30 . When tested in mammalian cells, both TLs blocked CME in a light-regulated manner. Between the two, Traffic Light 2 (TL2) proved particularly attractive as it is inert under dark-adapted conditions (trans isomer), but it strongly reduces CME trafficking upon activation with (ultra)violet light (cis isomer) (Fig. 1B) . Here, we demonstrate that the TL2 peptide designed for mammalian proteins retains its activity in yeast and provides a powerful tool to dynamically regulate CME. In contrast to small molecules, its peptide nature offers a higher degree of specificity to the mode of action, while the photoswitchable crosslinker enables both the spatiotemporal control of inhibition with light, and the permeability of the compound through the PM. 26 Although some peptides have been reported to penetrate the fungal cell-wall, this remains a prohibitive barrier to most macromolecules 31 . Since TL2 targets an intracellular protein-protein interaction, we first tested whether it could be internalized in yeast using an analogue labelled with carboxy-fluorescein (CF-TL2) on its N-terminus. S. cerevisiae and S. pombe were incubated in the presence of different peptide concentrations (dark-inactive TL2), but in no case, signs of internal fluorescence were detected, suggesting that cells were unable to take up the peptide or this was quickly extruded (Fig. S1 ). To evaluate if the cell wall might interfere with the peptide uptake, we proceeded to its enzymatic digestion with lyticase before exposing the cells to the fluorescent peptide. To prevent cell lysis, spheroplasts were maintained in media supplemented with 0.7 M sorbitol for osmotic support. A styryl dye, FM4-64 (16 µM), was used to selectively stain vacuole membranes with red fluorescence 32 . This allowed us to confirm that cell integrity, viability, and endocytic activity were maintained after the spheroplasting process. After coincubation in the presence of fluorescently labelled and dark-adapted inactive CF-TL2, a specific signal corresponding to the peptide was detected by fluorescence inverted optical microscopy in small cortical patches and bright bigger internal structures, as well as in the vacuole, whose limiting membrane was stained with FM4-64. In addition, a weaker signal in the cytosol was detectable. The data thus indicated that under these conditions CF-TL2 was most likely internalized into the cells via an endocytic pathway from where it could be translocated into the cytosol. To investigate the effect of light-activated TL2 on endocytosis, we followed the cortical dynamics of the GFPtagged coat-associated protein Sla1-GFP. The yeast clathrin adaptor Sla1 is a component of the clathrin coat, whose spatiotemporal dynamics at endocytic sites has been well-characterized 12, 13, 33 . Spheroplasts of S. cerevisiae expressing Sla1-GFP were treated with either pre-activated TL2 (380 nm) or with vehicle, and cortical patches were live-imaged after 30 minutes incubation. As shown by kymographs generated from 120 seconds time-lapse movies, light-activated TL2 significantly extended the permanence of the GFP-labelled endocytic patches on the PM (Fig. 3A) . This effect was dose-, time-, and light-dependent ( Fig. 3B-D) . Inhibition was observed between 50-100 µM and 20-30 min incubation ( Fig. 3B and 3D) . As lightinduced changes are observable close to the IC50 and far from saturating doses, 26 we chose 100 µM and 20 min to quantify light dependency. As reported in mammalian cells, 26 dark-adapted TL2 did not significantly alter CME, thus confirming that the peptide is also constitutively inert in yeast, and can stall CME upon UVinduced photoisomerization ( Fig. 3C and Fig. S2 ). Subsequently, we focused on characterizing the active isomer (UV-illuminated TL2, 100 µM) and the extent of its activity in S. cerevisiae spheroplasts. Live-cell imaging at different incubation times revealed how TL2 progressively delayed Sla1-GFP internalization resulting in both a shift and a broadening of the patches lifetime distribution when compared to vehicle (Fig. 3D) . The onset of CME inhibition was consistently observed after 20 minutes, which suggested that the peptide needed to be taken up by endocytosis before translocation to the cytosol. To investigate if clathrin coat assembly, and not only its kinetics, might also be affected by the activated TL2, we quantified both the average Sla1-GFP lifetime, as well as the number of endocytic events per minute after 30 min treatment. Upon plotting these two parameters for each cell, preactivated TL2-and vehicle-treated samples distributed into two markedly different populations (Fig. 3E) . CME inhibition associated with a moderate, but significant reduction in the number of endocytic foci (Fig. 3F) , which were 22% less frequent than in the control. We also investigated if the treatment affected later stages of CME (Fig. 3G-I) . In particular, patches were analysed for their phenotypes and classified according to their internalization patterns (Fig. 3G) . Normally, the endocytic coat moves into the cytosol as the endocytic invagination grows, and it disassembles as or shortly after the vesicles detach from the PM. In mutants unable to invaginate the plasma membrane though, the endocytic coat remains at the PM ("flat" phenotype). Finally, in mutants affecting the final scission event an initial inward movement of the coat can be observed, but then it bounces back towards the PM ("v-shaped" phenotype) (Fig. 3G) [34] [35] [36] [37] . TL2-treatment caused marginal changes in the percentage of flat or v-shaped phenotypes compared to vehicle, thus indicating that the peptide does not affect membrane invagination or scission but rather coat maturation and/or cargo loading (Fig. 3H) . Finally, we analysed the assembly and disassembly dynamics of the Sla1-GFP cortical patches in cells either mock-treated or treated with activated TL2. Sla1-GFP fluorescence intensity plots as a function of time were aligned at their peak intensity (set as time 0) (Fig. 3I) . Interestingly, while the assembly and disassembly rates appeared similar in both samples, TL2 produced a very significant increase of the maximum fluorescence signal at t=0, revealing that higher levels of Sla1 are required to sustain endocytic budding or that the coats grow larger in the presence of TL2, before initiating membrane invagination (Fig. 3I) . We have shown that the photoswitchable peptide TL2 designed from the sequence and structure of human β-arrestin C-terminus can be effectively used to photocontrol CME in yeast. As observed in mammalian cells, TL2 can cross the yeast membranes in minutes and accumulate at concentrations sufficient to inhibit CME. We interpret that pre-illuminated (cis, helical) TL2 binds to its target in a conformation that inhibits and slows down clathrin-coated pit (CCP) assembly and internalization, reducing the frequency of events and increasing their duration, thus diminishing the cellular rate of CME. In contrast, the trans, less-helical peptide appears inactive in the absence of illumination. Arrestin-like proteins (ARTs) exist in yeast, which as mammalian arrestins, act as E3 ubiquitin ligase cargo adaptors. Unlike mammalian arrestins though, yeast ARTs lack the specific residues that mediate binding to AP2 and clathrin 38, 39 (Fig. S3) . Therefore, it is likely that the mammalian arrestin function is split in yeast and that TL2 interferes with the clathrin adaptors for ubiquitinated cargo, rather than with the ARTs. In yeast, AP2 lacks the β2-appendage domain (residues 701-937) that in mammalians interacts with the βarrestin C-terminus and with TL2 through specific residues located in the protein platform subdomain 26, 40 . As the yeast α-appendage shares structural similarities with the mammalian β2-appendage, we investigated if the former could act as binding site of our peptide 27, 41 . Adaptin-binding motifs occasionally share similar sequences. In particular, an FXXφ hydrophobic core (where φ indicates a hydrophobic residue) is common to both [DE]nX1-2[FLI]XX[FL]XXXR and FXXFXXL motifs, which respectively bind the β2-and α-platform subdomains 27, 28, 41, 42 . In both cases, binding is mediated by two hydrophobic sites, which are present in both mammalian appendages and conserved in S. cerevisiae. In yeast, a first hydrophobic interaction might be mediated by F907 (mammalian β2-F837) and by I908 and V954, corresponding to mammalian β2-L838 and β2-A877, respectively. The second hydrophobic interaction might be mediated by W911 (β2-W841) and F972 (β2-Y888). In contrast, clusters of polar residues involved in [DE]nX1-2[FLI]XX[FL]XXXR binding are only found in the mammalian β2-subdomain and in the yeast α-appendage 27, 28 . In particular, the basic C-terminus of the peptide could interact with E921 and E982 (β2-E849 and β2-E902 in mammalian), whereas its Nterminal acidic region could interact with R956 (β2-R879 and β2-R834 in mammalians) (Fig. S4) . Despite being structurally conserved between lower and higher eukaryotes, AP2 plays a dispensable role in yeast 43, 44 . So far, no endocytic phenotype, apart from resistance to the killer toxin K28, has been associated with its knockout, hence it has been suggested that AP2 might act as an adaptor complex for cargoes that are dispensable to yeast viability 45 . Alternatively, the limited phenotypic consequences of deleting AP2 may be due to redundancy of adaptors and/or rerouting to other endocytic pathways. In contrast to genetic manipulation of the AP2 function in yeast, the acute (photo)pharmacological inhibition shown here suggests that AP2 has an important role in CME. We propose that, once the adaptor complex is recruited into the nascent CCP, TL2 can competitively interfere with protein-protein interactions necessary to advance through the internalization process. Upon binding to the AP2 appendages, TL2 mimics endogenous accessory proteins (clathrin-associated sorting proteins, CLASPs) and hinders progression maybe through the activation of regulatory checkpoints that impede vesicle internalization of incorrectly loaded cargoes 39, 46 . Hence, we hypothesize that TL2 acts as a dominant negative peptide exhibiting the AP2-binding motif, but lacking domains essential to regulate endocytic progression. This is supported by the fact that in mammalian models the overexpression of adaptin-binding motifs inhibits CME 42, 47 . Moreover, in S. cerevisiae the specific binding sequence of TL2 is conserved in several accessory proteins and the corresponding knockout strains display phenotypes that are reminiscent of those obtained upon treatment with TL2. For example, deletion of End3 leads to an increased persistence of Sla1-GFP at the cell cortex 13 , whereas deletion of Ede1 reduces the frequency of site initiations similarly to the presence of the pre-activated TL2, while shortening the lifetime of Sla1-GFP 13, 48, 49 . Interestingly, an Ede1(22A) mutant that lacks a phosphoregulatory site exhibits reduced patch density (by a 25%) without altering the lifetime of Sla1-GFP 48 . Thus, light-activated TL2 allows to assess the effect of interfering with the [DE]nX1-2[FLI]XX[FL]XXLR motif on several endocytic proteins and it results in a combination of phenotypes otherwise only appreciable by performing time-consuming, multiple mutations. In summary, we have characterized the TL2 activity in S. cerevisiae spheroplasts and proved that its ability to control CME with light spans throughout evolution. To the best of our knowledge, no other means to achieve specific pharmacological inhibition of CME have been described to be effective in yeast. While latrunculin A displays a dramatic effect over endocytic vesicle internalization, its inhibitory activity over actin-polymerization interferes with numerous other cellular functions. This, so far, has impeded to understand the contribution of CME to those processes, such as cytokinesis and cell migration, in which the actin role is crucial. In light of these considerations, we believe that TL2 provides a unique tool for the scientific community to gain deeper understandings over the function and regulation of CME. This photoswitchable inhibitor opens the way to intriguing studies where CME could be switch on and off at will using light, in order to synchronize it with other measurements (e.g. microscopy, biochemical reactions) or cellular processes, or obliterate it at specific cellular locations such as the cytokinetic ring or the growth pole. Clostridial glucosylating toxins enter cells via clathrin-mediated endocytosis Anthrax toxin triggers endocytosis of its receptor via a lipid raft-mediated clathrin-dependent process Tetanus toxin is internalized by a sequential clathrin-dependent mechanism initiated within lipid microdomains and independent of epsin 1 The role of clathrin-dependent endocytosis in bacterial internalization Endocytosis of viruses and bacteria Clathrin-Dependent Entry of Severe Acute Respiratory Syndrome Coronavirus into Target Cells Expressing ACE2 with the Cytoplasmic Tail Deleted SARS-CoV-2 infects cells following viral entry via clathrinmediated endocytosis. bioRxiv. 2020;pre-print Molecular mechanism and physiological functions of clathrin-mediated endocytosis Lessons from yeast for clathrin-mediated endocytosis Clathrin-mediated endocytosis in budding yeast Mechanisms of clathrin-mediated endocytosis A Pathway for association of receptors, adaptors, and actin during endocytic internalization A modular design for the clathrin-and actin-mediated endocytosis machinery Distinct acto/myosin-I structures associate with endocytic profiles at the plasma membrane Ultrastructural dynamics of proteins involved in endocytic budding Correlated fluorescence and 3D electron microscopy with high sensitivity and spatial precision Plasma Membrane Reshaping during Endocytosis Is Revealed by Time-Resolved Electron Tomography High rates of actin filament turnover in budding yeast and roles for actin in establishment and maintenance of cell polarity revealed using the actin inhibitor latrunculin-A Small molecules for dissecting endomembrane trafficking: A cross-systems view Modulating protein-protein interactions: The potential of peptides Search for inhibitors of endocytosis Ikarugamycin: A Natural Product Inhibitor of Clathrin-Mediated Endocytosis Disruption of endocytosis through chemical inhibition of clathrin heavy chain function Light-regulated stapled peptides to inhibit protein-protein interactions involved in clathrin-mediated endocytosis Role of the AP2 β-appendage hub in recruiting partners for clathrin-coated vesicle assembly Molecular switches involving the AP-2 β2 appendage regulate endocytic cargo selection and clathrin coat assembly A water-soluble azobenzene cross-linker for photocontrol of peptide conformation Absence of a stable secondary structure is not a limitation for photoswitchable inhibitors of β-arrestin/β-adaptin 2 protein-protein interaction Free uptake of cell-penetrating peptides by fission yeast A new vital stain for visualizing vacuolar membrane dynamics and endocytosis in yeast The Sla1 adaptor-clathrin interaction regulates coat formation and progression of endocytosis Distinct roles for F-BAR proteins Cdc15p and Bzz1p in actin polymerization at sites of endocytosis in fission yeast Characterization of dip1p reveals a switch in Arp2/3-dependent actin assembly for fission yeast endocytosis Determinants of endocytic membrane geometry, stability, and scission An Abp1-dependent route of endocytosis functions when the classical endocytic pathway in yeast is inhibited Regulation of receptor trafficking by GRKs and arrestins Arrestin-Related Ubiquitin-Ligase Adaptors Regulate Endocytosis and Protein Turnover at the Cell Surface Yeast endocytic adaptor AP-2 binds the stress sensor Mid2 and functions in polarized cell responses Evolving nature of the AP2 α-appendage hub during clathrin-coated vesicle endocytosis Solitary and repetitive binding motifs for the AP2 complex αappendage in amphiphysin and other accessory proteins Adaptor complex-independent clathrin function in yeast Clathrin functions in the absence of heterotetrameric adaptors and AP180-related proteins in yeast A yeast killer toxin screen provides insights into A/B toxin entry, trafficking and killing mechanisms Regulation of receptor fate by ubiquitination of activated β2-adrenergic receptor and β-arrestin. Science (80-) Curvature of clathrin-coated pits driven by epsin Casein Kinase 1 Promotes Initiation of Clathrin-Mediated Endocytosis Selection and stabilization of endocytic sites by Ede1, a yeast functional homologue of human Eps15 This research received funding from the European Union Research and Innovation Programme Horizon 2020 -Human Brain Project SG3 (945539), DEEPER (ICT-36-2020-101016787)-, Agency for Management of University and Research Grants/Generalitat de Catalunya (CERCA Programme; 2017-SGR-1442 and 2017-SGR-00465 projects), Fonds Européen de Dévelopement Économique et Régional (FEDER) funds, Ministry of Science and Innovation (Grant PID2019-111493RB-I00), Fundaluce and "la Caixa" foundations (ID 100010434, agreement LCF/PR/HR19/52160010). The project Clúster Emergent del Cervell Humà (CECH, 001-P-001682) is co-financed by the European Union Regional Development Fund within the framework of the ERDF Operational Program of Catalonia 2014-2020 with a grant of 50% of total eligible cost. IBEC and IRB Barcelona are recipient of a Severo Ochoa Award of Excellence from MINECO (Government of Spain). BFU2017-82959-P from MINECO to MIG. D.P. was supported by fellowship BES-2015-072657.